Key Developments: Transition Therapeutics Inc (TTHI.OQ)

TTHI.OQ on NASDAQ Stock Exchange Global Market

2.17USD
2 Jul 2015
Change (% chg)

$0.06 (+2.84%)
Prev Close
$2.11
Open
$2.07
Day's High
$2.17
Day's Low
$2.04
Volume
16,830
Avg. Vol
30,008
52-wk High
$9.30
52-wk Low
$2.03

Search Stocks

Latest Key Developments (Source: Significant Developments)

Transition Therapeutics announces results of clinical study of ELND005
Wednesday, 24 Jun 2015 06:01am EDT 

Transition Therapeutics:Announces results of clinical study of elnd005 in agitation and aggression in patients with alzheimer's disease.Phase 2/3 clinical study of neuropsychiatric drug candidate elnd005 did not meet its primary efficacy endpoint.Both treatment and placebo groups showed significant, but similar, reduction in agitation and aggression relative to baseline.  Full Article

Transition Therapeutics Inc appoints Carl Damiani as President
Tuesday, 16 Jun 2015 06:01am EDT 

Transition Therapeutics Inc:Appoints Carl Damiani as President and Chief Operating Officer of Transition.  Full Article

Transition Therapeutics announces results from phase 1 AME & Renal clearance clinical studies of neuropsychiatric drug candidate ELND005
Thursday, 26 Mar 2015 06:01am EDT 

Transition Therapeutics Inc:Announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005.These studies, an absorption-metabolism-excretion (AME) study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration (FDA) for the approval of most drugs in development.Says the AME study enrolled 8 subjects and the renal clearance study enrolled 42 subjects.Says in both studies, ELND005 showed good safety and tolerability.The key result of the AME study was that ELND005 showed good oral bioavailability as there was nearly 100 pct absorption.ELND005 showed no evidence of hepatic or intermediary metabolism and the study demonstrated that the main excretion route of ELND005 is via the kidney.  Full Article

Transition Therapeutics Inc announces closing of public offering of $23 mln of common shares
Wednesday, 18 Feb 2015 04:01pm EST 

Transition Therapeutics Inc:Announced the closing of its underwritten public offering of an aggregate of 3,538,461 common shares at a price to the public of $6.50 per share, including 461,538 common shares issued upon the exercise of the underwriters' over-allotment option.Cowen and Company, LLC was the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC were the co-managers for the offering.Expects to use the net proceeds from the sale of the common shares for general corporate purposes, including expenditures related to the advancement of the Company's drug candidates through the various clinical trial phases.  Full Article

Transition Therapeutics Inc announces pricing of public offering of $20 million of common shares
Thursday, 12 Feb 2015 08:00am EST 

Transition Therapeutics Inc:Says pricing of its underwritten public offering of 3,076,923 common shares at a price to the public of US$6.50 per share for total gross proceeds of $20 million.Company has granted the underwriters a 30-day option to purchase up to an additional 461,538 common shares, which could result in an additional $3 million of gross proceeds.The offering is expected to close on Feb. 18, subject to customary closing conditions.Says Cowen and Company, LLC is the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC are the co-managers for the offering.Company expects to use net proceeds from the sale of the common shares for general corporate purposes, including expenditures related to the advancement of the Company's drug candidates through the various clinical trial phases.  Full Article

Transition Therapeutics Inc announces public offering of common shares
Wednesday, 11 Feb 2015 04:01pm EST 

Transition Therapeutics Inc:Announces that it has commenced an underwritten public offering of its common shares.Expects to use net proceeds from the sale of the common shares for general corporate purposes, including expenditures related to the advancement of the Company's drug candidates through the various clinical trial phases.Cowen and Company, LLC is the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC are the co-managers for the offering.  Full Article

Transition Therapeutics Inc announces results from ELND005 clinical study in adults with Down Syndrome
Thursday, 20 Nov 2014 06:01am EST 

Transition Therapeutics Inc:Announced the results of a clinical study of neuropsychiatric drug candidate ELND005 in young adults with Down syndrome.Transition's wholly-owned subsidiary, Transition Therapeutics Ireland Limited (TTIL) completed this first study in Down syndrome subjects without dementia to allow optimal dose selection for future larger studies.Says the study enrolled 23 Down syndrome subjects in three study arms over a four-week treatment period: placebo (n=6), 250mg once daily (QD) (n=5), and 250mg twice daily (BID) (n=12).Says ELND005, at the doses evaluated, was determined to have an acceptable safety and tolerability profile and there were no serious adverse events reported in the study.Says the treatment emergent adverse events were reported in seven of the subjects receiving ELND005 and all were deemed to be mild in severity.Says the two ELND005 doses achieved the plasma levels expected in pharmacokinetic modeling and will inform the selection of a higher dose in a future clinical study.  Full Article

Transition Therapeutics Inc announces closing of private placement equity financing
Monday, 23 Jun 2014 06:01am EDT 

Transition Therapeutics Inc:Has closed private placement through which 3,195,487 units of company were purchased by Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders.Gross proceeds of private placement totalled $17 mln.Each unit consists of one common share, and 0.61 of common share purchase warrant with purchase price of $7.10 per whole warrant.  Full Article

Transition Therapeutics Inc enters into a private placement with investors to receive up to $30.8 mln in equity financing
Friday, 6 Jun 2014 09:01am EDT 

Transition Therapeutics Inc:Says Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders will make an investment of up to $30.8 mln.Says by purchasing 3,195,487 units of the company at a price of $5.32 per unit.Each unit consists of one common share, and 0.61 of a common share purchase warrant with a purchase price of $7.10 per whole warrant.Each whole warrant will entitle the holder, within two years from closing, to purchase one additional common share in the capital of the Company.If and when all of the warrants are exercised, the Company will realize an additional $13.8 mln, bringing the total investment to $30.8 mln before transaction costs.Closing of the private placement is expected to occur on or about June 20 and is subject to approval from the Toronto Stock Exchange.  Full Article

Transition Therapeutics Inc Announces Closing Of Private Placement Equity Financing
Thursday, 15 Aug 2013 04:36pm EDT 

Transition Therapeutics Inc announced that it has closed its previously announced private placement through which 2,625,300 units of the Company were purchased by Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders. Gross proceeds of the private placement totalled $11 million. As previously announced, each unit consists of (i) one common share, (ii) 0.325 Common Share purchase warrant with a purchase price of $4.60 per whole warrant and (iii) 0.4 Common Share purchase warrant with a purchase price of $6.50 per whole warrant. Each whole warrant will entitle the holder, within two years, to purchase one additional common share in the capital of the Company. If and when all of the warrants are exercised, the Company will realize an additional $10.7 million in proceeds.  Full Article

Search Stocks